The Analgesic Efficacy of Nefopam in Patient Undergoing Orthopedics Surgery with Tourniquet: a Double-blind Case-control Trial

Nefopam is a non-opioid, non-steroidal, centrally acting analgesic drug that is derivative of the non-sedative benzoxazocine, developed and known in 1960s as fenazocine. Although the mechanisms of analgesic action of nefopam are not well understood, they are similar to those of triple neurotransmitter (serotonin, norepinephrine, and dopamine) reuptake inhibitors and anticonvulsants. It has been used mainly as an analgesic drug for nociceptive pain, as well as a treatment for the prevention of postoperative shivering and hiccups. Based on nefopam's mechanisms of analgesic action, it is more suitable for the treatment of neuropathic pain. The recently discovered dual analgesic mechanisms of action, namely, a) descending pain modulation by triple neurotransmitter reuptake inhibition similar to antidepressants, and b) inhibition of long-term potentiation mediated by N-methyl-D-aspartate (NMDA) from the inhibition of calcium influx like gabapentinoid anticonvulsants or blockade of voltage-sensitive sodium channels like carbamazepine, enable nefopam to be used as a therapeutic agent to treat neuropathic pain. The investigators believe that nefopam could be a viable, safe and cost-effective choice to reduce pain scores resulting from orthopedic surgeries in addition to pain resulting from tourniquet insertion and reduce opioid requirements simultaneously with minimal side effects.

This study is a prospective, double-blind, case-control study conducted at the King Abdullah University Hospital in Jordan during the period of June 2023 to December 2023. The study protocol was approved by the Institutional Review Board of King Abdullah University Hospital and registered at the Clinical Research Information Service. Written informed consent was obtained from all participants before enrollment.

Eligible participants for this study included patients undergoing orthopedic surgery which involved usage of tourniquet under general anesthesia. Only patients aged 15-60 were included in the study. The exclusion criteria were as follows: patients with any contraindication to nefopam, surgery with tourniquet time more than 180 min, patients on opioid medications, patients with preexisting chronic pain syndromes, patients refuse to participate in the study and patients with psychiatric diseases. All participants were randomly divided into two groups (control and nefopam) in a 1:1 ratio using computer-generated randomization. A pharmacist who was not involved in this study handled normal saline or nefopam to the anesthesiologist according to the assigned group with the same drug labeling to ensure double blindness.

Intervention and anesthetic protocol Standard monitoring including electrocardiography, non-invasive blood pressure monitor, pulse oximetry, capnography, and neuromuscular monitoring, was applied to the patients throughout the procedure. Induction was performed using propofol 2mg/kg fentanyl 2 μg/kg and atracurium 0.5mg /kg. Inhalational anesthesia using isoflurane 1- minimum alveolar concentration (MAC) with atracurium was performed to maintain general anesthesia. Mechanical ventilation was controlled to maintain the end-tidal carbon dioxide partial pressure at 30-40 mmHg with an inhaled oxygen fraction of 40%-50%. Body temperature was monitored using an esophageal temperature probe and maintained above 35 °C with a forced air warmer. Neostigmine 2.5 mg with atropine 1mg was used to reverse muscle relaxation at the end of surgery.

The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg or placebo diluted with normal saline was infused over 20 min. At the end of surgery, all patients were given morphine 0.1 mg/kg or tramadol 1mg/kg for postoperative pain control. Morphine (5 mg) was provided as a rescue analgesic upon the patient's request when the postoperative pain score exceeded 4.